Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

This study has been completed.
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Cephalon ) Identifier:
First received: June 11, 2009
Last updated: September 20, 2012
Last verified: September 2012
The primary objective of this study is to assess the safety and tolerability of bendamustine as combination therapy with bortezomib for patients with relapsed/refractory multiple myeloma (MM).

Condition Intervention Phase
Multiple Myeloma
Drug: bendamustine
Drug: bortezomib
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

Resource links provided by NLM:

Further study details as provided by Teva Pharmaceutical Industries:

Primary Outcome Measures:
  • Participants With Dose Limiting Toxicity (DLT) [ Time Frame: Day 1 - 28 ]

    Maximum tolerated dose was the dose that was 1 step lower than the dose where at least one third of patients experienced DLT. A DLT was defined as any of the following occurring during the first cycle:

    • grade 4 hematologic toxicity without regard for relationship to study drug treatment
    • thrombocytopenia grade 3 with grade 3 or grade 4 hemorrhage
    • grade 3 febrile neutropenia
    • grade 3 or grade 4 nausea and vomiting refractory to anti emetic therapy
    • any study drug related grade 3 or grade 4 nonhematologic toxicity
    • any drug related death

    Toxicity grades (3=severe AE and 4=life-threatening or disabling AE) were assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.

Secondary Outcome Measures:
  • Percentage of Participants With An Overall Tumor Response As Assessed By the Investigator [ Time Frame: Up to 7.5 months (eight 28-day cycles) ]
    Overall tumor response is the sum of a complete response (CR), very good partial response (VGPR), partial response (PR) and minimal response (MR). A modified version of the Bladé criteria for response was used. Abbreviated definitions for the response categories can be found in the description of outcome #3.

  • Participants' Best Tumor Response as Assessed by the Investigator [ Time Frame: up to 7.5 months (eight 28-day cycles) ]
    Abbreviated criteria for response categories: CR includes the disappearance of the original monoclonal protein (M-protein) from blood and urine, and <5% plasma cells in the bone marrow, and no increase in size/number of lytic bone lesions, and disappearance of soft tissue plasmacytomas for >=4 weeks. VGPR includes serum and urine M-protein detectable by immunofixation but not electrophoresis, and reduction in 24-hr urinary light chain excretion by <100 mg, and disappearance of soft tissue plasmacytomas for >= 4 weeks, and no increase in size/number of lytic bone lesions. PR includes a >=50% reduction in serum M-protein, and reduction in 24-hr urinary light chain excretion by either >=90% or to <200 mg, and >=50% reduction in size of soft tissue plasmacytomas, and no increase in size/number of lytic bone lesions. MR includes a >=25% and <=49% reduction in serum M-protein. SD does not meet criteria for the other response categories. See outcome #4 for a definition of PD.

  • Kaplan-Meier Estimate for Time to Progression (TTP) [ Time Frame: up to 8.6 months ]

    Time to progression was defined as the time from initiation of therapy to progressive disease (PD). PD requires at least one of the following:

    • >25% increase in serum monoclonal paraprotein (which must also be an absolute increase of at least 5 g/L),
    • >25% increase in 24-hour urinary light chain excretion (which must also be an absolute increase of at least 200 mg/24 h),
    • >25% increase in plasma cells in a bone marrow aspirate or on trephine biopsy (which must also be an absolute increase of at least 10%),
    • definite increase in the size of existing lytic bone lesions or soft tissue plasmacytomas,
    • the development of new bone lesions or soft tissue plasmacytomas,
    • the development of hypercalcemia (corrected serum calcium > 11.5 mg/dL or 2.8 mmol/L not attributable to any other cause).

  • Kaplan-Meier Estimate for Progression-Free Survival [ Time Frame: up to 23 months ]
    Progression free survival is the time between the date of initiation of therapy to progressive disease (PD) or death from any cause, whichever occurs first. See outcome #4 for a definition of PD.

  • Time to the First Response [ Time Frame: up to 8.5 months ]
    Time to first response is defined as the time from the initiation of therapy to the first evidence of a confirmed response (ie, CR, VGPR, PR, or MR).

  • Kaplan-Meier Estimate for Duration of Response [ Time Frame: up to 8.5 months ]
    Duration of response (DR) is defined as the time from the first response to progressive disease (PD). See outcome #4 for a PD definition.

  • Kaplan-Meier Estimate for Overall Survival (OS) [ Time Frame: up to 23 months ]
    Overall survival is defined as the time from initiation of therapy to death from any cause or last follow-up visit.

  • Summary of Participants With Adverse Events (AEs) [ Time Frame: up to 8.5 months. Deaths are reported up to 18 months ]
    Counts of participants who had AEs are summarized in a variety of categories. Severity and relatedness to study drug are in the opinion of the investigator according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0. Severity is rated on a 5-point scale: 1=mild, 2=moderate, 3=severe, 4=life threatening or disabling, and 5= death related to AE. Relatedness is assessed on a 5-point scale: not related, unlikely, possible, probable and definite. Definite, probable and possible answers are reported as 'related' to study medication. Deaths are reported up to 18 months. All the deaths occurred beyond the treatment-emergent timeframe since they occurred 6.5-16 months after the final dosing. All other parts of the summary represent the treatment-emergent timeframe (up to 8.5 months) which is the treatment period plus 30 days.

Enrollment: 40
Study Start Date: June 2009
Study Completion Date: December 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Bendamustine and Bortezomib
Bendamustine in escalating doses of 50, 70 or 90 mg/m^2 as combination therapy with bortezomib at 1.0 mg/m^2/dose administered for up to eight 28 day cycles.
Drug: bendamustine

Bendamustine was administered to 3 cohorts of patients at escalating doses of 50 (cohort 1), 70 (cohort 2) and 90 mg/m^2/dose (cohort 3). Doses were administered by intravenous (iv) infusion once daily on days 1 and 4 of each 28-day cycle. Each iv was administered over 60 minutes and followed the injection of bortezomib.

Bortezomib will be administered to patients at a dose of 1.0 mg/m2/dose as an iv push over 3 to 5 seconds followed by a standard saline flush or through a running iv line. Doses are to be administered to patients on days 1, 4, 8 and 11 of the 28-day cycle.

Other Names:
  • CEP-18083
  • Bendamustine hydrochloride
Drug: bortezomib
Bortezomib was administered at a dose of 1.0 mg/m^2/dose as an intravenous (iv) push over 3 to 5 seconds followed by a standard saline flush or through a running iv line. Doses are to be administered on days 1, 4, 8 and 11 of each 28-day cycle.
Other Name: VELCADE®


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

The patient:

  • has a diagnosis of multiple myeloma.
  • currently has multiple myeloma with measurable disease.
  • must have received at least 1 previous treatment regimen and shows signs of progressive disease at the time of study entry.
  • if a woman of child bearing potential (not surgically sterile or at least 12 months naturally postmenopausal), must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 30 days after participation in the study.
  • if a man, must agree to use an acceptable method of contraception throughout the study and for 90 days after last dose study drug.
  • must have an Eastern Cooperative Oncology Group (ECOG) performance status not greater than 2.
  • must have a life-expectancy of greater than 3 months.
  • must meet specific protocol-related hematological and laboratory criteria within 14 days of enrollment.

Exclusion Criteria:

The patient has:

  • had a prior malignancy within the last 5 years (except for basal or squamous cell carcinoma, or in situ cancer of the cervix).
  • plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein (M-protein) and skin changes (POEMS) syndrome.
  • plasma cell leukemia.
  • non-measurable multiple myeloma.
  • Common Terminology Criteria for Adverse Events (CTCAE) grade 2 (or greater) peripheral neuropathy within 14 days before enrollment.
  • previously participated in a Cephalon-sponsored clinical study with bendamustine.
  • impaired cardiac function or clinically significant cardiac diseases.
  • undergone major surgery within 4 weeks prior to screening or has not recovered from side effects of such therapy.
  • severe hypercalcemia.
  • other concurrent severe and/or uncontrolled medical or psychiatric conditions.
  • known positivity for human immunodeficiency virus (HIV) or hepatitis B or C.
  • a history of allergic reaction attributable to compounds of similar chemical or biological composition to bendamustine, bortezomib, boron, or mannitol.
  • received chemotherapy within 3 weeks before enrollment, with the exception of nitrosoureas, which should be discontinued at least 6 weeks before enrollment.
  • received corticosteroids (greater than 10 mg/day prednisone or equivalent) within 3 weeks before enrollment.
  • received immunotherapy, antibody, or radiation therapy within 4 weeks before enrollment.
  • a status as a pregnant or lactating woman. Any women becoming pregnant during the study will be withdrawn from the study.
  • a status as a male whose sexual partner is a woman of childbearing potential not using effective birth control.
  • used an investigational drug within 1 month before the screening visit.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00920855

United States, California
Pacific Oncololgy & Hematology
Encinitas, California, United States
Capitol Hematology Oncology
Roseville, California, United States
University Of California, San Diego
San Diego, California, United States
James R. Berenson, M.D., Inc.
West Hollywood, California, United States
United States, District of Columbia
George Washington University
Washington, District of Columbia, United States
United States, Illinois
Northshore University Health System
Evanston, Illinois, United States
United States, Maryland
Alivin & Lois Lapidus Cancer Institute
Baltimore, Maryland, United States
Center for Cancer and Blood Disorders
Bethesda, Maryland, United States
United States, Massachusetts
Sophia Gordon Cancer Center at Lahey Clinic
Burlington, Massachusetts, United States
United States, Pennsylvania
Geisinger Medical Center
Danville, Pennsylvania, United States
United States, South Carolina
Charleston Hematology Oncology, PA
Charleston, South Carolina, United States
United States, Tennessee
Family Cancer Center, PLLC
Collierville, Tennessee, United States
United States, Virginia
Fairfax Northern Virginia Hematology Oncology
Fairfax, Virginia, United States
Sponsors and Collaborators
Study Director: Sponsor's Medical Expert Cephalon
  More Information

Berenson JR, Yellin O, Bessudo A, et al. Bendamustine combined with bortezomib has efficacy in patients with relapsed or refractory multiple myeloma: a phase 1/2 study. Blood (ASH Annual Meeting Abstracts). 2011;118 (suppl 21):abstract 1857

Responsible Party: Cephalon Identifier: NCT00920855     History of Changes
Other Study ID Numbers: C18083/1063/MM/US
Study First Received: June 11, 2009
Results First Received: August 15, 2012
Last Updated: September 20, 2012

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Bendamustine Hydrochloride
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action processed this record on April 28, 2017